Investors & Media

Ionis announces eplontersen receives orphan drug designation from U.S. FDA

CARLSBAD, Calif. , Jan. 24, 2022 /PRNewswire/ — Ionis Pharmaceuticals , Inc. (Nasdaq: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to eplontersen, an investigational antisense medicine for the

Read more
You are now leaving to visit